| 目录号 | 品名 | 物种 | 靶点 | 表达细胞系 |
| NBR-1000 | Anti-ALCAM / CD166 Reference Antibody (Praluzatamab-MMAE) | Human | ALCAM / CD166 | CHO |
| NBR-1001 | Anti-AMHR2 Reference Antibody (Murlentamab-MMAE) | Human | AMHR2 | CHO |
| NBR-1002 | Anti-AXL / UFO Reference Antibody (Enapotamab vedotin) | Human | AXL / UFO | CHO |
| NBR-1003 | Anti-AXL / UFO Reference Antibody (Tilvestamab-MMAE) | Human | AXL / UFO | CHO |
| NBR-1004 | Anti-MUC16 Reference Antibody (oregovomab-MMAE) | Human | CA125 / MUC16 | CHO |
| NBR-1005 | Anti-MUC16 Reference Antibody (Sofituzumab vedotin) | Human | CA125 / MUC16 | CHO |
| NBR-1006 | Anti-CA9 / CAIX Reference Antibody (girentuximab-MMAE) | Human | CA9 / Carbonic anhydrase 9 | CHO |
| NBR-1007 | Anti-CD19 Reference Antibody (denintuzumab-MMAF) | Human | CD19 | CHO |
| NBR-1008 | Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) | Human | CD79b | CHO |
| NBR-1009 | Anti-CD79b Reference Antibody (iladatuzumab vedotin) | Human | CD79b | CHO |
| NBR-1010 | Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab govitecan) | Human | CEACAM5 / CEA / CD66e | CHO |
| NBR-1011 | Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab-MMAE) | Human | CEACAM5 / CEA / CD66e | CHO |
| NBR-1012 | Anti-CLDN18.2 Reference Antibody (zolbetuximab MMAE) |
| CLDN18.2 | CHO |
| NBR-1013 | Anti-CXCR4/CD184 Reference Antibody (ulocuplumab-MMAE) | Human | CXCR4 / CD184 | CHO |
| NBR-1014 | Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) | Human | DLL3 | CHO |
| NBR-1015 | Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) | Human | Endoglin / CD105 | CHO |
| NBR-1016 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab-MMAF) | Human | ERBB1 / EGFR / HER1 | CHO |
| NBR-1017 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Cetuximab-MMAE) | Human | ERBB1 / EGFR / HER1 | CHO |
| NBR-1018 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Disitamab vedotin) | Human | ERBB2 / HER2 / CD340 | CHO |
| NBR-1019 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Trastuzumab-MMAE) | Human | ERBB2 / HER2 / CD340 | CHO |
| NBR-1020 | Anti-ERBB3/ HER3 Reference Antibody (patritumab-MMAE) | Human | ERBB3 / HER3 | CHO |
| NBR-1021 | Anti-ERBB3/ HER3 Reference Antibody (Patritumab deruxtecan) | Human | ERBB3 / HER3 | CHO |
| NBR-1022 | Anti-FOLH1 / PSMA Reference Antibody (rosopatamab-MMAE) | Human | FOLH1 / PSMA | CHO |
| NBR-1023 | Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) | Human | FOLR1 / FRA | CHO |
| NBR-1024 | Anti-FOLR1 / FRA Reference Antibody (mirvetuximab-MMAE) | Human | FOLR1 / FRA | CHO |
| NBR-1025 | Anti-GD3 Reference Antibody (ecromeximab-MMAE) | Human | GD3 | CHO |
| NBR-1026 | Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) | Human | GPC3 / Glypican-3 | CHO |
| NBR-1027 | Anti-GPNMB Reference Antibody (Glembatumumab vedotin) | Human | GPNMB | CHO |
| NBR-1028 | Anti-GUCY2C Reference Antibody (Indusatumab vedotin) | Human | GUCY2C | CHO |
| NBR-1029 | Anti-HGFR / c-Met Reference Antibody (Telisotuzumab vedotin) | Human | HGFR / c-Met | CHO |
| NBR-1030 | Anti-IL-3Ra / CD123 Reference Antibody (talacotuzumab-MMAE) | Human | IL-3Ra / CD123 | CHO |
| NBR-1031 | Anti-KAAG1 Reference Antibody (ADCT-901-MMAE) | Human | KAAG1 | CHO |
| NBR-1032 | Anti-LIV-1 / SLC39A6 Reference Antibody (Ladiratuzumab vedotin) | Human | LIV-1 / SLC39A6 | CHO |
| NBR-1033 | Anti-Mesothelin Reference Antibody (anetumab-MMAE) | Human | Mesothelin | CHO |
| NBR-1034 | Anti-MU5AC Reference Antibody (ensituximab-MMAE) | Human | MU5AC | CHO |
| NBR-1035 | Anti-MUC1 Reference Antibody (clivatuzumab-MMAE) | Human | MUC1 | CHO |
| NBR-1036 | Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) | Human | NaPi2b / SLC34A2 | CHO |
| NBR-1037 | Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab-MMAE) | Human | NCAM1 / CD56 | CHO |
| NBR-1038 | Anti-Nectin-4 Reference Antibody (enfortumab vedotin-ejfv) | Human | Nectin-4 | CHO |
| NBR-1039 | Anti-ROR1 Reference Antibody (Zilovertamab vedotin) | Human | ROR1 | CHO |
| NBR-1040 | Anti-ROR2 Reference Antibody (ozuriftamab vedotin) | Human | ROR2 | CHO |
| NBR-1041 | Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) | Human | Siglec-2 / CD22 | CHO |
| NBR-1042 | Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) | Human | Siglec-2 / CD22 | CHO |
| NBR-1043 | Anti-SLITRK6 Reference Antibody (Sirtratumab vedotin) | Human | SLITRK6 | CHO |
| NBR-1044 | Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (tisotumab vedotin) | Human | TF / Factor III / Tissue Factor / CD142 | CHO |
| NBR-1045 | Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) | Human | TNFRSF8 / CD30 | CHO |
| NBR-1046 | Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) | Human | TNFSF7 / CD27L / CD70 | CHO |
| NBR-1047 | Anti-TROP2 Reference Antibody (datopotamab deruxtecan) | Human | TROP2 | CHO |
| NBR-1048 | Anti-TROP2 Reference Antibody (Sacituzumab-MMAE) | Human | TROP2 | CHO |
收缩
